新华牌品牌怎么样 申请店铺

外推网助力新华牌品牌出海！通过在本页面挂载新华牌品牌的产品链接和联系邮箱，可以提高新华牌产品曝光！跨境电商爆单神器，目前只要100元/年哦~

新华制药的前身是1943年成立于胶东抗日根据地的山东新华制药厂。公司占地近300多万平方米，现有职工4000多人。是大型制药企业、亚洲较大的解热镇痛类药物生产与出口基地，以及国内重要的心脑血管类、抗感染类及中枢神经类等药物生产企业。在我国化工及医药行业具有较高的企业地位和影响力。公司是H股、A股上市公司。目前旗下有9家控股子公司。“新华牌”商标是商务部培育和发展的出口品牌。

目前，公司年产化学原料药总量3.5万吨以上，是全球较大的安乃近、布洛芬、阿司匹林、咖啡因、左旋多巴等药物生产企业，拥有乙氧苯柳胺等10个原料药品种，制剂年生产能力为片剂达80亿片、针剂10亿支、胶囊15亿粒、颗粒剂2亿袋。生产上严把质量关，精益求精。公司是国内通过ISO9001、ISO14001、ISO10012三项认证的医药化工企业，所有在产原料药产品、制剂剂型均已通过GMP认证，茶碱、布洛芬等8个产品通过了美国FDA认证，茶碱、阿司匹林等10个产品获得了欧洲COS证书，咖啡因产品通过了美国用户的社会责任认证、环境认证，以及中国食品安全体系（HACCP）认证。同时有多个产品在俄罗斯、印度等国家完成了注册。

公司经过70多年发展，已建成总厂区、新华国际医药工业园东园、西园、新园区四大生产园区，形成了化学原料药、医药制剂、医药化工中间体、医药商业四大板块齐头并进的合理布局。未来公司将坚持以科学发展观统领全局，以四大园区、四大板块为依托，以自主创新为动力，以结构优化升级为抓手，以主导产品为龙头，以收购扩充产业链为发展策略。以药为主、精干主业，做好辅业——以房地产置业反哺制药主业的发展，做精做大原料药、医药化工中间体，突出做强制剂的发展思路。坚定不移地走科学发展、和谐发展、国际化发展之路，练内功，拓市场，调结构，增效益，实现又好又快发展，为我国医药事业发展做出新的更大的贡献！

The predecessor of Xinhua Pharmaceutical was established in Shandong Xinhua Pharmaceutical Factory in Jiaodong Anti Japanese base in 1943. The company covers an area of more than 3 million square meters and has more than 4000 employees. It is a large pharmaceutical enterprise, a large production and export base of antipyretic and analgesic drugs in Asia, as well as an important domestic drug manufacturer of cardio cerebrovascular, anti infective and central nervous system. It has a high status and influence in the chemical and pharmaceutical industry in China. The company is a listed company with H shares and a shares. At present, it has 9 holding subsidiaries. "Xinhua brand" is an export brand cultivated and developed by the Ministry of Commerce. At present, the company has an annual output of more than 35000 tons of chemical APIs. It is the world's largest pharmaceutical manufacturer of analgin, ibuprofen, aspirin, caffeine, levodopa and other drugs. It has 10 APIs such as ethoxybenzamide, with an annual production capacity of 8 billion tablets, 1 billion injections, 1.5 billion capsules and 200 million bags of granules. Strictly control the quality in production and keep improving. The company is a domestic pharmaceutical and chemical enterprise that has passed three certifications of ISO9001, ISO14001 and ISO10012. All the products and preparations of APIs in production have passed GMP certification. Eight products, such as theophylline and ibuprofen, have passed FDA certification in the United States. Ten products, such as theophylline and aspirin, have obtained European cos certificate. Caffeine products have passed social responsibility certification and environmental certification of American users, And China's food safety system (HACCP) certification. At the same time, many products have been registered in Russia, India and other countries. After more than 70 years of development, the company has built four production parks, namely the general plant area, the East Park, the West Park and the new park of Xinhua International Pharmaceutical Industrial Park, forming a reasonable layout of four plates, namely, chemical raw materials, pharmaceutical preparations, pharmaceutical chemical intermediates and pharmaceutical commerce. In the future, the company will adhere to the concept of scientific development to guide the overall situation, relying on four parks and four plates, with independent innovation as the driving force, with structural optimization and upgrading as the starting point, with leading products as the leader, and with acquisition and expansion of industrial chain as the development strategy. Focus on medicine, concentrate on main business, and do a good job in auxiliary business - feed back the development of the main pharmaceutical business with real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate real estate. Unswervingly follow the road of scientific development, harmonious development and international development, practice internal skill, expand market, adjust structure, increase benefit, realize sound and rapid development, and make new and greater contribution to the development of China's pharmaceutical industry!

本文链接： https://brand.waitui.com/7cc2179ac.html 联系电话：请联系客服添加